Nikhil C. Munshi, MD
Adjunct Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Hematology & Medical Oncology

MBBS, Maharaja Sayajirao University
MD, Maharaja Sayajirao University



Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.

A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.

Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.

VA Boston Healthcare System






Title
Integrative Oncogenomics of Multiple Myeloma
(PI)

SPORE in Multiple Myeloma
(PI)

Molecular Manipulation to Enhance Anti-Myeloma Response
(PI)



Yr Title Project-Sub Proj Pubs
2025 Molecular Manipulation to Enhance Anti-Myeloma Response 5I01BX001584-11
2024 Molecular Manipulation to Enhance Anti-Myeloma Response 5I01BX001584-10
2024 Core 1: Administrative Core 5P01CA155258-12-8234
2024 Project 4: Targeting genomic instability and evolution in myeloma 5P01CA155258-12-8233
2024 Integrative Oncogenomics of Multiple Myeloma 5P01CA155258-12
2023 Molecular Manipulation to Enhance Anti-Myeloma Response 2I01BX001584-09
2023 Integrative Oncogenomics of Multiple Myeloma 2P01CA155258-11
2023 Project 4: Targeting genomic instability and evolution in myeloma 2P01CA155258-11-8233
2023 Core 1: Administrative Core 2P01CA155258-11-8234
2023 SPORE in Multiple Myeloma 5P50CA100707-20
Showing 10 of 100 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Morelli E, Aktas Samur A, Maisano D, Gao C, Favasuli VK, Papaioannou D, De Nola G, Henninger JE, Liu N, Turi M, Folino P, Vreux L, Cumerlato M, Chen L, Aifantis I, Fulciniti M, Anderson KC, Lytton-Jean AK, Gulla A, Young R, Samur MK, Munshi NC. CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs. Blood. 2025 May 22. PMID: 40403231
     
  2. Morelli E, Ribeiro CF, Rodrigues SD, Gao C, Socciarelli F, Maisano D, Favasuli V, Liu N, Todoerti K, Chakraborty C, Yao Y, Fulciniti M, Samur M, Aktas-Samur A, Amodio N, Turi M, Barello F, Penailillo J, Giallongo C, Romano A, Gulla A, Anderson KC, Inghirami G, Munshi NC, Loda M. Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma. Clin Cancer Res. 2025 May 15; 31(10):1975-1987. PMID: 40053701; PMCID: PMC12081190; DOI: 10.1158/1078-0432.CCR-24-2000;
     
  3. Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC. Editor's Note: Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2025 May 15; 31(10):2063. PMID: 40370044
     
  4. Giorgetti G, Maroto-Martin E, Soncini D, Fenoglio D, Becherini P, Benzi A, Ravera S, Traverso I, Ladisa F, Lai F, Rivoli G, Truffelli D, Nahimana A, Cagnetta A, Guolo F, Uras CRM, Schavgoulidze A, Fong Ng J, Nencioni A, Bruzzone S, Munshi NC, Lemoli RM, Fulciniti M, Cea M. CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma. Blood Cancer J. 2025 May 02; 15(1):83. PMID: 40316562; PMCID: PMC12048669; DOI: 10.1038/s41408-025-01284-y;
     
  5. Perini T, Zordan P, Del Pizzo R, Resnati M, Viviani L, Stefanoni D, Cassina L, Orfanelli UP, Trudu M, Oliva L, Lacidogna D, Samur MK, Materozzi M, Drago D, Andolfo A, Patrone M, Degano M, Boletta A, Milan E, Ciceri F, Munshi NC, Bellone M, Cenci S. The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma. Blood. 2025 Apr 29. PMID: 40300074
     
  6. Frenking JH, Zhou X, Rejeski K, Wagner V, Costello P, Hielscher T, Gatti L, Kauer J, Nadeem O, Mai EK, Michel CS, Friedrich MJ, Sedloev DN, Weinhold N, Goldschmidt H, Herfarth K, Schmitt A, Hundemer M, Schmitt M, Müller-Tidow C, Topp MS, Einsele H, Dreger P, Munshi NC, Sperling AS, Rasche L, Sauer S, Raab MS. Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myeloma. Blood Adv. 2025 Apr 23. PMID: 40267180
     
  7. Paiva B, Shi Q, Puig N, Cedena MT, Orfao A, Durie BGM, Munshi NC, San-Miguel J. Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma. Nat Rev Clin Oncol. 2025 Apr 07. PMID: 40195455
     
  8. Chakraborty C, Talluri S, Binder M, Morelli E, Mayoral JE, Derebail S, Aktas Samur A, Epstein CB, Anderson KC, Shammas MA, Samur MK, Fulciniti M, Munshi NC. Loss of BCL7A Permits IRF4 Transcriptional Activity and Cellular Growth in Multiple Myeloma. Blood. 2025 Mar 16. PMID: 40090008
     
  9. Waldschmidt JM, Sotudeh N, Arora S, Vijaykumar T, Anand P, Stuart H, Frede J, Campbell T, Kaiser SM, Zheng X, Munshi NC, Anderson KC, Einsele H, Yee AJ, Knoechel B, Lohr JG, Raje NS. Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma. Blood Adv. 2025 Mar 11; 9(5):1132-1136. PMID: 39813623; PMCID: PMC11914164; DOI: 10.1182/bloodadvances.2024015285;
     
  10. Nardone C, Gao J, Seo HS, Mintseris J, Ort L, Yip MCJ, Negasi M, Besschetnova AK, Kamitaki N, Gygi SP, Dhe-Paganon S, Munshi N, Fulciniti M, Greenberg ME, Shao S, Elledge SJ, Gu X. Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma. bioRxiv. 2025 Feb 23. PMID: 40027645; PMCID: PMC11870617; DOI: 10.1101/2025.02.22.639686;
     
Showing 10 of 622 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 622 publications over 31 distinct years, with a maximum of 32 publications in 2021 and 2024

YearPublications
19931
19961
19975
19987
199914
20006
200115
200226
200325
200416
200516
200619
200720
200820
200926
201021
201125
201222
201328
201425
201529
201623
201727
201829
201920
202025
202132
202226
202324
202432
202517

Contact for Mentoring:

Munshi's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department